Table 2.
Patient baseline demographic and clinical characteristics in cohort 2 (Apatinib plus Chemotherapy vs. Chemotherapy Alone)
| Initial cohort | Propensity-score-matched cohort | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Apatinib plus Chemotherapy (n = 34) |
Chemotherapy Alone (n = 97) |
P | Apatinib plus Chemotherapy (n = 27) |
Chemotherapy Alone (n = 27) |
P | ||||
| Age, years | |||||||||
| < 50 | 15 (44.1) | 49 (50.5) | 0.658 | 13 (48.1) | 16 (59.3) | 0.585 | |||
| ≥ 50 | 19 (55.9) | 48 (49.5) | 14 (51.9) | 11 (40.7) | |||||
| ECOG PS at start | |||||||||
| 0 | 5 (14.7) | 11 (11.3) | 0.833 | 3 (11.1) | 1 (3.7) | 0.603 | |||
| ≥ 1 | 29 (85.3) | 86 (88.7) | 24 (88.9) | 26 (96.3) | |||||
| Menopausal status at diagnosis | |||||||||
| Premenopausal | 23 (67.6) | 71 (73.2) | 0.691 | 19 (70.4) | 20 (74.1) | 1.000 | |||
| Postmenopausal | 11 (32.4) | 26 (26.8) | 8 (29.6) | 7 (25.9) | |||||
| Surgery on primary tumor | |||||||||
| Yes | 20 (58.8) | 74 (76.3) | 0.084 | 17 (63.0) | 22 (81.5) | 0.224 | |||
| No | 14 (41.2) | 23 (23.7) | 10 (37.0) | 5 (18.5) | |||||
| TNBC at the initial onset | |||||||||
| Yes | 30 (88.2) | 70 (72.2) | 0.096 | 24 (88.9) | 24 (88.9) | 1.000 | |||
| No | 4 (11.8) | 27 (27.8) | 3 (11.1) | 3 (11.1) | |||||
| Ki67 ≥ 30% | 29 (85.3) | 85 (87.6) | 0.958 | 23 (85.2) | 25 (92.6) | 0.665 | |||
| Metastatic sites | |||||||||
| Visceral | 19 (55.9) | 53 (54.6) | 1.000 | 13 (48.1) | 15 (55.6) | 0.785 | |||
| Non-visceral | 15 (44.1) | 44 (45.4) | 14 (51.9) | 12 (44.4) | |||||
| Metastatic sites > 3 | 9 (26.5) | 50 (51.5) | 0.020 | 8 (29.6) | 10 (37.0) | 0.773 | |||
| Location of metastases | |||||||||
| Brain | 1 (2.9) | 6 (6.2) | 0.779 | 0 | 0 | NA | |||
| Bone | 12 (35.3) | 45 (46.4) | 0.356 | 8 (29.6) | 8 (29.6) | 1.000 | |||
| Liver | 5 (14.7) | 19 (19.6) | 0.707 | 4 (14.8) | 4 (14.8) | 1.000 | |||
| Lung | 15 (44.1) | 41 (42.3) | 1.000 | 11 (40.7) | 13 (48.1) | 0.784 | |||
| Lymph node | 25 (73.5) | 70 (72.2) | 1.000 | 19 (70.4) | 20 (74.1) | 1.000 | |||
| Adrenal glands | 0 | 2 (2.1) | 0.975 | 0 | 0 | NA | |||
| Chest wall | 3 (8.8) | 13 (13.4) | 0.691 | 3 (11.1) | 4 (14.8) | 1.000 | |||
| (Neo-) Adjuvant therapies | |||||||||
| Paclitaxel/Docetaxel | 20 (58.8) | 63 (64.9) | 0.666 | 17 (63.0) | 18 (66.7) | 1.000 | |||
| Anthracyclines | 20 (58.8) | 71 (73.2) | 0.177 | 17 (63.0) | 18 (66.7) | 1.000 | |||
| Paclitaxel/Docetaxel and Anthracyclines | 20 (58.8) | 61 (62.9) | 0.830 | 17 (63.0) | 18 (66.7) | 1.000 | |||
| Platinum (Cis/Carbo) | 2 (5.9) | 3 (3.1) | 0.833 | 2 (7.4) | 1 (3.7) | 1.000 | |||
| Capecitabine | 2 (5.9) | 3 (3.1) | 0.833 | 2 (7.4) | 1 (3.7) | 1.000 | |||
| Treatment | |||||||||
| anti-PD-1/L1 antibody | 0 | 0 | NA | 0 | 0 | NA | |||
| Nab-paclitaxel | 11 (32.4) | 11 (11.3) | 0.011 | 6 (22.2) | 5 (18.5) | 1.000 | |||
| Eribulin | 3 (8.8) | 10 (10.3) | 1.000 | 2 (7.4) | 2 (7.4) | 1.000 | |||
| Paclitaxel/Docetaxel | 2 (5.9) | 34 (35.1) | 0.002 | 2 (7.4) | 1 (3.7) | 1.000 | |||
| Other chemotherapy (Platinum, Capecitabine, Gemcitabine, NVB, etc.) | 24 (70.6) | 80 (82.5) | 0.219 | 22 (81.5) | 25 (92.6) | 0.418 | |||
| Lines of therapy | |||||||||
| 1st Line | 6 (17.6) | 53 (54.6) | < 0.001 | 6 (22.2) | 6 (22.2) | 1.000 | |||
| 2nd+ Line | 28 (82.4) | 44 (45.4) | 21 (77.8) | 21 (77.8) | |||||